AllRock Bio

AllRock Bio is a clinical-stage biotechnology company focused on advancing treatments for cardiopulmonary and fibrotic diseases. The company's lead candidate, ROC-101, is a first-in-class oral pan-ROCK inhibitor being developed to address the urgent unmet needs of pulmonary arterial hypertension (PAH) and other life-threatening fibrotic diseases. With an experienced leadership team and a commitment to addressing unmet needs, AllRock is dedicated to bringing a new class of disease-modifying therapies to patients.